Sanofi
↗Paris, France
Sanofi is a multinational pharmaceutical and healthcare company headquartered in Paris, France. The company is engaged in the discovery, development, manufacturing, and marketing of medicines, vaccines, and healthcare solutions. With operations in 100 countries and a global workforce of approximately 82,878 employees, Sanofi is focused on transforming patient care through innovative therapies in immunology, oncology, neurology, rare diseases, and vaccines. The company generated €47.9 billion in revenue in 2024 with a strong focus on science-driven R&D, investing €8.0 billion (18% of sales) in research and development. In 2025, Sanofi is undergoing a strategic transformation, transitioning from a diversified healthcare company to a focused, pure-play biopharma organization following the separation of its consumer healthcare division (Opella).
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Integrated Pharmaceutical & Vaccine Company
SIZE & FINANCIALS
Employees:10000+
Revenue:$47-48B
Founded:1973
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ, Euronext Paris
Ticker:SNY
Market Cap:$117.16B
PIPELINE
Stage:Preclinical through Phase 3
Lead Drug Stage:Phase 3 and commercial stage
Modalities:Small molecule, Monoclonal antibodies (mAb), Antibody-drug conjugates (ADC), Bispecific antibodies, NANOBODY®, Gene therapy, Cell therapy, mRNA, siRNA, NK cell therapies
Trial Phases:Phase 3: 36
FDA Approvals:14
CORPORATE STRUCTURE
Subsidiaries:Sanofi Pasteur (vaccines division), Opella (consumer healthcare - 48.2% stake retained, separated April 2025), Genzyme (specialty care, integrated 2011)
Key Partnerships:Regeneron Pharmaceuticals (Dupixent collaboration since 2007, joint development and commercialization), Teva Pharmaceuticals (duvakitug - anti-TL1A monoclonal antibody for IBD), Johnson & Johnson (ExPEC vaccine - discontinued 2025), Orano Med (targeted alpha therapies for oncology - October 2024), Blueprint Medicines (acquisition announced June 2025 for up to $9.5B)
COMPETITION
Position:Leader
Competitors:Pfizer, Novartis, Roche, Merck, AbbVie, Bristol Myers Squibb, Amgen, AstraZeneca +7 more
LEADERSHIP
Key Executives:
Paul Hudson - Chief Executive Officer
Houman Ashrafian - Executive Vice President, Head of Research & Development
Olivier Charmeil - Executive Vice President, General Medicines
Natalie Bickford - Executive Vice President, Chief People Officer
Madeleine Roach - Head of Business Operations
Emmanuel Frenehard - Chief Digital Officer
Frédéric Oudéa - Chairman of the Board
Board Members:Frédéric Oudéa (Chairman), Paul Hudson (CEO and Director), Rachel Duan, Lise Kingo, Clotilde Delbos, Anne-Françoise Nesmes, John Sundy, Jean-Paul Kress (joined January 2025, independent director; formerly CEO of MorphoSys), Two employee representatives
LINKS
Website:sanofi.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sanofi. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.